Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Primary Care Respiratory Journal
  • View all journals
  • Search
  • Log in
  • Content Explore content
  • About the journal
  • Publish with us
  • RSS feed
  1. nature
  2. primary care respiratory journal
  3. review articles
  4. article
Earlier diagnosis and earlier treatment of COPD in primary care
Download PDF
  • Review Article
  • Published: 24 September 2010

Earlier diagnosis and earlier treatment of COPD in primary care

  • David Price1,
  • Daryl Freeman1,
  • Jen Cleland1,
  • Alan Kaplan2 &
  • …
  • Frank Cerasoli3 

Primary Care Respiratory Journal volume 20, pages 15–22 (2011)Cite this article

  • 6673 Accesses

  • 86 Citations

  • 71 Altmetric

  • Metrics details

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive disease that begins many years before a diagnosis is usually made. The need for an early and confirmed diagnosis of COPD is increasingly appreciated by primary care physicians in whose hands the ability to make improvements in early diagnosis largely rests. Case-finding of patients with symptoms of lifestyle limitation is probably the most practical way to achieve early diagnosis. Evidence suggests a burden of early COPD on afflicted people and their families. Early encouragement of smoking cessation, in conjunction with management of symptoms and treating activity limitation and exacerbations by appropriate non-pharmacologic and pharmacologic management at the earliest possible stage, could positively affect the impact and progression of the disease.

You have full access to this article via your institution.

Download PDF

Similar content being viewed by others

Prevalence, diagnostic accuracy, and healthcare utilization patterns in patients with COPD in primary healthcare: a population-based study

Article Open access 21 March 2025

Chronic obstructive pulmonary disease as a risk factor in primary care: a Canadian retrospective cohort study

Article Open access 24 June 2021

Does multimorbidity result in de-prioritisation of COPD in primary care?

Article Open access 14 January 2023

Article PDF

Author information

Authors and Affiliations

  1. Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK

    David Price, Daryl Freeman & Jen Cleland

  2. Chairperson, Family Physician Airways Group of Canada, Richmond Hill, Ontario, Canada

    Alan Kaplan

  3. Pfizer Inc, New York, NY, USA

    Frank Cerasoli

Authors
  1. David Price
    View author publications

    Search author on:PubMed Google Scholar

  2. Daryl Freeman
    View author publications

    Search author on:PubMed Google Scholar

  3. Jen Cleland
    View author publications

    Search author on:PubMed Google Scholar

  4. Alan Kaplan
    View author publications

    Search author on:PubMed Google Scholar

  5. Frank Cerasoli
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to David Price.

Ethics declarations

Competing interests

David Price has consultant arrangements with Aerocrine, Boehringer Ingelheim, Dey Pharmaceuticals, GlaxoSmithKline, Merck, Sharpe and Dohme, Novartis, Schering-Plough and Teva. He has received grants and research support for research in respiratory disease from UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Sharpe and Dohme, Novartis, Pfizer, Schering Plough and Teva. He has spoken for Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Sharpe and Dohme, Pfizer and Teva. Daryl Freeman has no shares in pharmaceutical companies. She has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory products: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline. She has received honoraria for advisory panels with AstraZeneca, and help with research projects from AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline. Daryl receives funding for a clinical post from AstraZeneca & Boehringer Ingelheim, and has recently been funded to attend an international conference by Nycomed & Boehringer Ingelheim. Jennifer Cleland has received unconditional educational research grants from Pfizer, GlaxoSmithKline and Boehringer Ingelheim. Alan Kaplan has worked or consulted for the following companies: AstraZeneca, Bayer, Boehringer Ingeleheim, GlaxoSmithKline, Merck Frost, Novartis, Nycomed, Pfizer, Purdue, and Talecris. Frank Cerasoli is an employee of Pfizer Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Price, D., Freeman, D., Cleland, J. et al. Earlier diagnosis and earlier treatment of COPD in primary care. Prim Care Respir J 20, 15–22 (2011). https://doi.org/10.4104/pcrj.2010.00060

Download citation

  • Received: 31 March 2010

  • Revised: 23 July 2010

  • Accepted: 29 July 2010

  • Published: 24 September 2010

  • Issue date: March 2011

  • DOI: https://doi.org/10.4104/pcrj.2010.00060

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

  • Development and validation of a nomogram to predict pulmonary function and the presence of chronic obstructive pulmonary disease in a Korean population

    • Sang Chul Lee
    • Chansik An
    • Chang Hoon Han

    BMC Pulmonary Medicine (2021)

  • Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD

    • Kate M. Johnson
    • Mohsen Sadatsafavi
    • Stirling Bryan

    Applied Health Economics and Health Policy (2021)

  • COPD Exacerbations: A Patient and Physician’s Perspective

    • John Linnell
    • John R. Hurst

    Advances in Therapy (2020)

  • Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective

    • Dave Singh
    • Anthony D. D’Urzo
    • Edward M. Kerwin

    Respiratory Research (2019)

  • Comorbidities according to airflow limitation severity: data from comprehensive health examination in Japan

    • Shota Masuda
    • Hisamitsu Omori
    • Takahiko Katoh

    Environmental Health and Preventive Medicine (2017)

You have full access to this article via your institution.

Download PDF

Associated content

Detecting mild COPD: don't waste resources

  • Paul Enright
  • Patrick White
Primary Care Respiratory Journal Editorial 10 Feb 2011

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Sign up for alerts
  • RSS feed

About the journal

  • Journal Information

Publish with us

  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Primary Care Respiratory Journal (Prim Care Respir J)

ISSN 1475-1534 (online)

nature.com footer links

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2026 Springer Nature Limited

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing